This document provides an overview of Merck, a global healthcare company. It discusses Merck's mission to save and improve lives through innovative pharmaceutical products and services. It outlines Merck's history and values, which include a commitment to ethics, access to medicines, and diversity. The document also discusses Merck's leadership, compliance programs, and views on issues like healthcare reform, innovation, and expanding global access to medicines and vaccines.

1. THIS DOCUMENT HAS THE PURPOSE OF
PRESENT WHO IS MERCK, WHAT IT DOES
AND ITS PROPOSALS FOR THE PRESENT
AND FUTURE HEALTH PROBLEMS SUCH AS
IVH, AIDS.
MERCK AS A COMPANY HAS HAD A BIG
DEVELOPMENT IN THE PHARMACEUTICAL
MARKET, THING THAT IT HAS RAISED BY ITS
INTEREST IN DISCOVER NEW MEDICINES
AS SOON A POSSIBLE TO CONTROL AND
CURE THE ILLNESS THAT ARE RUNNING
WITH THE PEOPLE´S LIFE.
ALEJANDRA CAROLINA OSSA
JUAN SEBASTIAN BETANCUR M
VANESSA LEON URIBE
06/10/2011

2. 2
TABLA DE CONTENIDO
MERCK ................................................................................................................................................................ 3
Our Vision ....................................................................................................................................................... 3
Our Mission .................................................................................................................................................... 3
What We Stand For ........................................................................................................................................ 3
OUR HISTORY...................................................................................................................................................... 3
ABOUT US ........................................................................................................................................................... 3
OUR VALUES ....................................................................................................................................................... 5
RESPONSIBILITY ETHICS AND TRANSPARENCY ................................................................................................... 7
LEADERSHIP ........................................................................................................................................................ 7
HOW WE OPERATE ............................................................................................................................................. 8
CODE OF CONDUCT ............................................................................................................................................ 9
COMPLIANCE ...................................................................................................................................................... 9
OUR COMMITMENT TO PRIVACY ..................................................................................................................... 10
VIEWS AND POSITIONS ..................................................................................................................................... 11
ACCESS AND AFFORDABILITY ........................................................................................................................... 11
HEALTHCARE REFORM ..................................................................................................................................... 12
INNOVATION .................................................................................................................................................... 13
QUALITY & SAFETY ........................................................................................................................................... 13
SALES & MARKETING ........................................................................................................................................ 14
RESPONSIBLE PUBLIC POLICY AND ADVOCACY ................................................................................................ 14
ACCESS .............................................................................................................................................................. 15
ENVIRONMENT ................................................................................................................................................. 15
DISCOVERY AND DEVELOPMENT ...................................................................................................................... 16
COMMUNITY: FIGHTING HIV/AIDS ................................................................................................................... 16
Report from the United Nations about the AIDS in the 2010 ...................................................................... 17
Graphic No. 1: The number of people surviving with HIV continues to increase due to life-prolonging
treatments ................................................................................................................................................... 18
Graphic No. 2: Treatment for HIV and AIDS is widespread, but not enough to meet the goal of universal
access by 2010 ............................................................................................................................................. 19
Graphic No. 3: Work is progressing steadily in reducing HIV transmission to newborns ............................ 20
CONSUMER PRODUCTS .................................................................................................................................... 21
1. ISENTRESS® .......................................................................................................................................... 21
2. CRIXIVAN® ........................................................................................................................................... 22
CONCLUSION .................................................................................................................................................... 22
REFERENCES ..................................................................................................................................................... 23

3. 3
MERCK
Our Vision
We make a difference in the lives of people globally through ourinnovative
medicines, vaccines, and consumer health and animal products. We aspire to be
the best healthcare company in the world and are dedicated to providing leading
innovations and solutions for tomorrow.
Our Mission
To provide innovative, distinctive products and services that save and improve
lives and satisfy customer needs, to be recognized as a great place to work, and to
provide investors with a superior rate of return.
What We Stand For
- Excellence in science and healthcare innovation, with an emphasis on
addressing unmet medical needs.
- Focus on patients and anticipating customers’ needs.
- Commitment to expand access to our medicines and vaccines, and to
improve global health.
OUR HISTORY
We've done great things in the past. Today, we're doing great things for the future.
Merck and Schering-Plough merged in November 2009 to create a new company.
Today, we are the second-largest healthcare company in the world. We also are a
global leader in consumer products and animal care.
Through the years, our researchers have helped to find new ways to treat and
prevent illness - from the discovery of vitamin B1, to the first measles vaccine, to
cold remedies and antacids, to the first statins to treat high cholesterol. Our
scientists also have helped develop many products to improve animal health,
including vaccines and antibiotics.
ABOUT US

4. 4
TICKER
MRK
NAME The company is known as Merck in the United States and Canada.
Everywhere else, we are known as MSD.
Merck & Co., Inc. is the legal name and is listed on the New York
Stock Exchange under the symbol "MRK."
Merck is an innovative, global healthcare leader that is committed to
improving health and well-being around the world.
Our product offering categories include heart and respiratory health,
infectious diseases, sun care and women's health. We continue to
focus our research on conditions that affect millions of people
around the world - diseases like Alzheimer's, diabetes and cancer -
DESCRIPTION while expanding our strengths in areas like vaccines and biologics.
We also devote extensive time and energy to increasing access to
medicines and vaccines through far-reaching programs that donate
and deliver our products to the people who need them.
At Merck, we're applying our global reach, financial strength and
scientific excellence to do more of what we're passionate about:
improving health and improving lives.
Merck. Be Well.
EMPLOYEES
Approximately 93,000 employees worldwide (as of 3/31/11)
HEADQUARTERS
Whitehouse Station, New Jersey
BUSINESSES Pharmaceuticals
Alliances
Consumer Care
Animal Health
2010 GAAP Merck $46.0 billion
Revenue
2010 REVENUES United States $20.2 billion
MERCK Europe, Middle East and Africa $13.5 billion
(By Geographic Japan $3.8 billion
Region) Other $8.5 billion
2010 R&D Merck $11.0 billion
EXPENSE
Merck is a global health care company that delivers innovative

5. 5
PRODUCTS health solutions through its prescription medicines, vaccines,
biologic therapies, and consumer and animal health products.
Kenneth C. Frazier, president and chief executive officer
EXECUTIVE Richard S. Bowles III, Ph.D., executive vice president and chief
COMMITTEE compliance officer
Peter S. Kim, Ph.D., executive vice president and president, Merck
Research Laboratories
J. Chris Scalet, executive vice president, Global Services, and chief
information officer
Adam H. Schechter, president, Global Human Health
Mervyn Turner, Ph.D., chief strategy officer and senior vice
president, Emerging Markets R&D, Merck Research Laboratories
Sources: Merck be well
OUR VALUES
As an organization, our core values are driven by a desire to improve human life,
achieve scientific excellence, operate with the highest standards of integrity,
expand access to our products and employ a diverse workforce that values
collaboration.
- Improving human life
Our business is preserving and improving human life. We also work to
improve animal health.
All of our actions must be measured by our success in achieving these
goals.
- Ethics & integrity
We are committed to the highest standards of ethics and integrity.
We are responsible to our customers, to Merck employees, to the
environments we inhabit, and to the societies we serve worldwide.

6. 6
In discharging our responsibilities, we do not take professional or ethical
shortcuts. Our interactions with all segments of society must be transparent
and reflect the high standards we profess.
- Innovation
We are dedicated to the highest level of scientific excellence.
Our research is guided by a commitment to preserving human and animal
health and the quality of life.
We strive to identify the most critical needs of consumers and customers,
and through continuous innovation we challenge ourselves to meet those
needs.
- Access for all
We aspire to improve the health and wellness of people around the world by
expanding access to our medicines and vaccines.
Creating new therapies is only the first step in battling disease and
promoting wellness on a global scale.
Success can only be achieved when everyone who needs our medicines
and vaccines can get them. In the United States and abroad, we've
developed numerous programs to help improve access to our products so
that all can benefit, wherever they live. One example of this situation is the
donation of a medicine called MECTIZAN®T through the program of
donation of MECTIZAN of MERCK to more than 30 countries around the
world, such as Brazil, Colombia, Guatemala, Ecuador, Venezuela and
Mexico.
- Diversity & teamwork
Our ability to excel depends on the integrity, knowledge, imagination, skill,
diversity and teamwork of our employees.
To this end, we work to create an environment of mutual respect,
encouragement and teamwork.
We reward commitment and performance and are responsive to the needs
of our employees and their families.

7. 7
RESPONSIBILITY ETHICS AND TRANSPARENCY
Because millions of people around the world depend on our products, we have
high standards for how we should conduct ourselves as a company.
Our chief compliance officer, who reports directly to the CEO, is responsible for
ensuring high ethical standards and compliance across our business globally. This
includes: making sure that the company complies with all applicable laws and
regulations.
Our Office of Ethics supports our commitment to the highest standards of ethics
and integrity in all of our business practices. We map out clear expectations for
employees and hold them accountable for their behavior. We also have a number
of mechanisms available such as an Ombudsman office and global AdviceLine to
help counsel employees who face challenging situations.
We also remain committed to operating openly and with integrity. We have taken
significant steps recently to improve transparency, committing to public disclosure
of our financial support for third-party groups and for healthcare providers who
speak on behalf of Merck or our products. We also make sure that study results of
our marketed products-regardless of outcome-are made available quickly on
ClinicalTrials.gov.
LEADERSHIP
How we govern ourselves as a company is as important as anything else we do.
Good corporate governance benefits both our customers and our shareholders,
and is essential to our long-term business success.
For this reason, we devote considerable time and resources to making sure that:
 our policies reflect our values and business goals;
 we have an effective corporate governance structure; and
 we are operating in a way that is open, honest and transparent.

8. 8
HOW WE OPERATE
Our goal is to lead the way to a healthier future. But we also care about how we get
there together.
As a company whose products touch the lives and well being of people around the
world, we hold ourselves to a high standard. And we expect others to hold us to
that same high standard.
Diversity at Merck
We also value the diverse contributions of our employees around the world, and
are committed to creating a workplace that is open, welcome and respectful of all
of our employees.
“These values and principles are at the heart of who we are as a company.”
Diversity is the power of differences. We believe that having a diverse, inclusive
workforce and organization makes us a more innovative and agile company,
attuned to the needs of our customers.
Every day, we strive to create an inclusive workplace, where diverse
perspectives are respected and all opinions matter:
 Diversity is woven throughout our business practices and training
strategy.
 Our leaders are accountable for specific objectives related to diversity
and inclusion. Results are measured in terms of individual, division and
company-wide performance.
 We provide equal employment opportunities to all qualified job
applicants.
 We cast a wide net in our search for talent, seeking qualified suppliers –
large and small – from all segments of the business community. This
includes minority-, women- and veteran-owned businesses.

9. 9
CODE OF CONDUCT
Our values and standards are the basis of our success. They always have been.
They always will be.
The people who use, recommend or prescribe our products have placed their trust
in us. No matter how strong our reputation, we must re - earn that trust every day
by practicing the values and standards that have guided this company for more
than 100 years.
Our code of conduct, which we publish for employees under the title Our Values
and Standards, helps to make sure that our employees understand what is
expected of them, and provides guidance on business standards and practices.
This is just one of the many ways that we continually reinforce the values on which
this company was built.
COMPLIANCE
Being an ethical company is about much more than simply adhering to the letter of
the law. But it’s an important step.
As part of our long-standing commitment to ethics and good corporate citizenship,
our first step is always to comply with the laws and regulations that govern the way
we market and sell our medicines, vaccines and other products.
We have a well-established compliance program that:
 is consistent with recommendations set forth by the U.S. Department of
Health and Human Services and the Code on Interactions with
Healthcare Professionals created by the Pharmaceutical Research and
Manufacturers of America (PhRMA);
 seeks to prevent, detect and resolve potential violations of law or
company policy; and
 undergoes regular assessment and adjustment to make sure we are
being responsive to our evolving business and associated compliance
risks.

10. 10
In addition, we:
 require employees to report potential violations of law or company
policy;
 hold ourselves accountable for responding promptly when potential
violations arise;
 take disciplinary action as appropriate; and
 examine whether identified violations are in part due to gaps in our
policies, practices or internal controls and, if so, take appropriate action
to prevent future violations.
Our compliance program is just one part of our overall commitment to operating
ethically, openly and transparently. But we believe it’s the right place to start.
OUR COMMITMENT TO PRIVACY
The new Merck privacy program is built on a strong foundation of global privacy
practices and standards and carries on our tradition of upholding high ethical
standards in collecting, using and disclosing personal information across our
business practices and in addressing privacy-related ethical issues in biomedical
research.
Privacy Trust at Merck:
We believe that trust is core to our privacy mission, so we have developed our
privacy program around the following key elements of privacy trust:
T - "transparency" - being open and clear about how we collect, use
and disclose personal information
R - "respecting choices" - such as whether or not people want to
participate in our programs
U - "understanding perspectives" - including that people have
different levels of concern about their privacy based on cultural
perspectives and personal experiences
S - "security" - protecting personal information from loss, misuse and
unauthorized access, disclosure, alteration or destruction

11. 11
T - treating our stakeholders with respect and in a manner consistent
with the Company's values
VIEWS AND POSITIONS
We support public policies that advance the interests of patients, improve public
health and promote access to medicines and innovation.
We work to achieve our business objectives responsibly and respond to our many
stakeholders' needs and concerns. We support policies that promote the discovery
of innovative medicines and vaccines and make these products available to all who
need them.
To advance this objective, we:
 develop policy positions that guide our activities and advocacy on a
range of issues;
 seek opportunities to adopt industry-leading standards in several areas;
 strive to communicate clearly and transparently about our positions;
and
 work closely with the many groups and individuals who are also trying
to address the complex healthcare challenges that confront us.
ACCESS AND AFFORDABILITY
Through our business operations, public policy, and outreach efforts, we work to
adopt progressive positions and advocate for change that will improve access to
medicines and vaccines, while balancing our ability to continue to develop
innovative products to address healthcare needs.
The issues related to access are varied and complex. Our approach seeks to
combine our strengths and abilities, working in close partnership with governments,
donors, patient organizations, healthcare professionals, nongovernmental
organizations, multilateral organizations, and others in the private sector.
We are taking steps to advance this objective:

12. 12
Through a multi-pronged strategy, we are improving access to medicines and
vaccines by examining our approach to research and development, manufacturing
and supply, registration, commercialization, and community investment.
In the developing world, including Africa and parts of Latin America and Asia, we
believe we have an important role and responsibility to help accelerate access to
our medicines and vaccines where access is most lacking. Access is determined
by many interrelated elements – some countries may lack basic medical
infrastructure, some patients may have limited access to hospitals or clinics, or in
some places there may be shortages of trained healthcare personnel. We have
taken this into account in our own work and how we work with others. We engage
in a wide range of public/private partnerships and other collaborations to spur
progress and new approaches to fighting diseases that affect the developing world,
such as AIDS.
In developed countries, access to medicines may be reduced by a lack of
affordable healthcare coverage or long waiting times before innovative medicines
are approved or made broadly available. We believe greater access can be
achieved through a strategy that combines the following:
 pricing our products responsibly and, where necessary, donating our
products to those who lack healthcare coverage, such as through our
U.S. patient assistance programs;
 advocating for healthcare reforms that will allow citizens greater access
to treatment and care through programs such as Medicare in the United
States. View our position on healthcare reform in the United States; and
 promoting and participating in public/private partnerships to address
chronic and infectious disease and other complex health challenges.
HEALTHCARE REFORM
Merck believes all Americans should have access to quality, affordable health
insurance coverage. We are working to support healthcare reform in the U.S.
There are about 47 million people in the U.S. who do not have healthcare
coverage. And that number grows every year.
We believe the country must come together on this issue and we support
bipartisan healthcare reform that will ensure access to affordable healthcare
coverage for all Americans.

13. 13
We are hopeful that our participation in the healthcare reform process and our
support for specific policies will help generate solutions that provide affordable
health insurance coverage for all.
INNOVATION
Innovation is the lifeblood of Merck. That is why we invested almost $5 billion in
research and development activities in 2008. Yet investment alone is not enough to
guarantee success.
Drug research is a high-risk and time-consuming process. Only 1 out of every
5000-10,000 compound screened becomes an approved drug. It takes an average
of 10 to 15 years at an average cost of more than US$1 billion to develop a
successful medicine.1
To deliver important products to the people who need them, we need a global
environment that supports the following enabling factors:
 Intellectual Property Protection
 Competition-based Healthcare
 Government Support for Basic Biomedical Research
 Evidence-based Regulatory Environment
 Global Business Environment
QUALITY & SAFETY
From research and development to the manufacturing and distribution of our
medicines, vaccines and other products, safety and quality are our first
considerations.
We are committed to manufacturing quality products and demand equivalent
standards from our suppliers to help ensure patient safety.
Some of our quality and safety systems include:
 Quality standards: We maintain policies, processes and procedures to help
ensure product quality.

14. 14
 Quality systems: Our global quality systems, made up of policies, processes
and procedures, are designed to ensure consistent product quality worldwide.
 Education and training: We provide ongoing education and training
programs on quality and cGMP and on Good Clinical Practice (GCP) for our
employees.
 Supplier standards: We maintain strict quality standards and insist on the
same from our suppliers and licensees, regardless of their location.
 Adverse event reporting: We maintain an Adverse Event Reporting
database and global procedures to compile adverse event information and
ensure compliance regulations globally.
 Safety monitoring: We have developed processes and procedures for the
timely and accurate monitoring of the safety profiles of our investigational and
marketed products.
SALES & MARKETING
We know that doctors and patients look to us to provide accurate and balanced
information about our products. We adhere to strict ethical sales and marketing
practices for all of our businesses, whether pharmaceuticals, vaccines, consumer
health or animal health.
We believe direct-to-consumer (DTC) advertising contributes to greater awareness
about conditions and diseases, which can benefit public health by increasing the
number of patients appropriately diagnosed and treated.
Our interactions with healthcare providers, other customers and consumers are
governed by laws and regulations, and by our global code of conduct which
includes standard business practices and compliance guidance. We take these
responsibilities seriously and periodically evaluate our marketing, sales and
advertising activities to ensure they align with the applicable laws, regulations and
Merck's policies and values.
RESPONSIBLE PUBLIC POLICY AND ADVOCACY
Merck is committed to participating constructively and responsibly in the political
process. Government proposals to regulate the health care system may directly

15. 15
affect the company's business and incentives for pharmaceutical innovation. Also,
there are important policy initiatives that can further the company's goals with
respect to increasing patient access to medicines and vaccines -- particularly for
patients in disadvantaged communities and regions -- and, most importantly, to
health care insurance coverage. It is appropriate for the company to help inform
the debate on these issues in the United States and in other countries, and to do
so in a responsible and ethical way.
ACCESS
We discover and develop medicines and vaccines for millions of people around the
world. But that’s not enough if people can’t access them.
We know that not everyone who needs our medicines and vaccines can get them –
whether because of an inability to see a doctor for a diagnosis or to pay for a
needed treatment.
In the United States, we are working to support much-needed reform of the
country’s healthcare system so people have insurance coverage. In the meantime,
we continue to make available and enhance our Patient Assistance Program so the
uninsured can receive our medicines and vaccines for free.
In other parts of the world, we have created numerous programs and public/private
partnerships to help improve healthcare capacity and improve access to our
products so all can benefit, wherever they live.
ENVIRONMENT
We at Merck remain dedicated to being environmentally responsible in how we
manufacture our medicines and vaccines. And we work hard to reduce our
environmental impact through stewardship of natural resources like water, by
conserving energy and also by appropriately eliminating waste.
We also go beyond the direct impact of our business to positively influence the
environment. Our main way of doing so is through financial support of non-
governmental organizations and their local partners to protect ecological resources
around the world.

16. 16
DISCOVERY AND DEVELOPMENT
The work we do in our labs has helped to save and improve countless lives.
Thanks to our world-class researchers, state-of-the-art technologies and
unrelenting focus on scientific excellence, Merck is at the forefront of discovering
and developing new ways to treat and prevent disease.
Scientific discovery and development have always been the cornerstones of our
company. Today, we conduct research in a broad range of therapeutic categories –
including cardiovascular disease, infectious diseases, vaccines, cancer, neurology
and women’s health. And, to help achieve our goal of saving and improving lives
around the world, we are expanding our capabilities in new areas, such as
biologics.
COMMUNITY: FIGHTING HIV/AIDS
Working in Partnership against HIV/AIDS
In 2000, in response to the massive threat HIV and AIDS posed in the sub-
Saharan nation of Botswana, Merck joined with the Government of Botswana and
the Bill & Melinda Gates Foundation to form the African Comprehensive HIV/AIDS
Partnerships. The Merck Company Foundation committed an initial $56.5 million to
the partnership to provide treatment, care and support for people living with HIV
and AIDS, as well as to help prevent its further spread. In addition, Merck agreed
to donate its antiretroviral medicines to Botswana's national antiretroviral treatment
program for the partnership's duration.
The partners selected Botswana because it had one of the highest adult
prevalence rates of HIV and AIDS in the world, a viable existing healthcare
infrastructure and strong political will and commitment to address the challenges of
HIV and AIDS.
In 2007, ACHAP expanded its support to target co-infection of HIV and
tuberculosis (TB). HIV infection has fueled an explosive increase in TB cases in
Botswana since the early 1990s.
Building on the successes created by its initial investment, in 2010 Merck
contributed an additional $30 million over the next five years. The new funding will
continue the program's original efforts in treatment and care but also will support
the second phase initiatives to meet the current treatment needs of the 137,000

17. 17
Batswana (people from Botswana) living with HIV and new patients enrolled in the
second phase. The second phase initiatives include: the prevention of HIV.
Report from the United Nations about the AIDS in the 2010
Sources: elmundo.es

18. 18
Graphic No. 1: The number of people surviving with HIV continues to
increase due to life-prolonging treatments
Sources: CINU
Between 2004 and 2009, the number of people receiving antiretroviral treatment
for HIV or AIDS was multiplied by 13. As a result, deaths from this disease during
this period decreased by 19%. In addition to fewer new infections, infected people
live longer.
In 2009 there were 33.3 million people living with HIV, 27% more than in 1999.
Sub-Saharan Africa remains the region most affected: it has 69% of new HIV
infections, 68% of all HIV-positive population and 72% of AIDS deaths. However,
the epidemic has spread to other regions.

19. 19
Graphic No. 2: Treatment for HIV and AIDS is widespread, but not enough
to meet the goal of universal access by 2010
Sources: CINU
In late 2009, in countries with low and middle income had 5.25 million people
receiving antiretroviral therapy. This represents an increase of more than 1.2
million people compared to December 2008, which saw the largest annual increase
ever recorded.
Some countries, including Botswana, Cambodia, Croatia, Cuba, Guyana, Oman,
Romania and Rwanda, have already achieved universal access (defined as
coverage of at least 80% of the population in need) to antiretroviral treatment and /
or interventions prevent HIV transmission.
The World Health Organization (WHO) revised its guidelines in 2009 regarding the
treatment of HIV-positive adults and adolescents, including pregnant women. As a

20. 20
result, the number of people needing antiretroviral therapy defined increased from
10.1 to 14.6 million in late 2009.
Graphic No. 3: Work is progressing steadily in reducing HIV transmission
to newborns
Sources: CINU
Without treatment of the mother, about one third of children of HIV positive women
will become infected with the virus during pregnancy, childbirth or breastfeeding.
This risk can be greatly reduced if the pregnant woman is treated with antiretroviral
therapy.
In 2009, the number of HIV positive pregnant women receiving antiretroviral
therapy treatment was 53%, which only reached 45% in 2008. About 91% of the
1.4 million pregnant women needing treatment live in sub-Saharan Africa.

21. 21
CONSUMER PRODUCTS
Through our consumer health products, we strive to enhance the quality of life for
people and their families around the world.
Each day, millions count on one or more of our industry-leading brands that help
prevent or treat various common conditions.
There are the most important and effectly product that we have to control the
human immunodeficiency virus (AIDS), which are:
1. ISENTRESS®
ISENTRESS is a human immunodeficiency virus integrase strand transfer
inhibitor (HIV-1 INSTI); an anti-HIV (antiretroviral) medicine used for the
treatment of HIV.
This medicine works blocking an enzyme called HIV integrase which the virus
(HIV) needs in order to make more virus.
Isentress is used in the mayority of cases with other anti-HIV medicines to
reduce the amount of the Human Immunodeficiency Virus (HIV) in the blood
and increase the number of white blood cells.
INGREDIENTS
Active ingredient: Each film-coated tablet contains 400 mg of raltegravir.
Inactive ingredients: Microcrystalline cellulose, lactose monohydrate, calcium
phosphate dibasic anhydrous, hypromellose 2208, poloxamer 407 (contains
0.01% butylated hydroxytoluene as antioxidant), sodium stearyl fumarate,
magnesium stearate. In addition, the film coating contains the following inactive
ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol 3350, talc,
red iron oxide and black iron oxide.

22. 22
2. CRIXIVAN®
CRIXIVAN is an oral capsule used for the treatment of HIV (Human
Immunodeficiency Virus). HIV is the virus that causes AIDS (acquired immune
deficiency syndrome). CRIXIVAN is a type of HIV drug called a protease (PRO-
tee-ase) inhibitor.
CRIXIVAN is a protease inhibitor that fights HIV. CRIXIVAN can help reduce
your chances of getting illnesses associated with HIV. CRIXIVAN can also help
lower the amount of HIV in your body (called “viral load”) and raise your CD4
(T) cell count. CRIXIVAN may not have these effects in all patients.
CRIXIVAN is usually prescribed with other anti-HIV drugs such as ZDV (also
called AZT), 3TC, ddI, ddC, or d4T. CRIXIVAN works differently from these
other anti-HIV drugs. Talk with your doctor about how you should take
CRIXIVAN.
CONCLUSION
From this document we can observer that MERCK is an important and recognized
company that has a good position in the global pharmaceutical market and has
been involved in the discovering of infinitive of medicines to improve the human
and animal health.
MERCK is one of the most interested in help to save the humans from illnesses
that are destroying them; one example of this is the donation o medicine to control
the AISD and the intervention on the healthcare reform in The United States to
improve the human welfare and reduce de mortality rate.
In summary and to end we can say that MERCK with its discovers and thought to
the future could be a excellent group with the government of each country
interested in improve the human welfare to try of raising all their projects together.

23. 23
REFERENCES
- Source: Merck be well
http://www.merck.com/about/Merck%20Corporate%20Ads.pdf, retrieved on
September 24 of 2011.
- Source: CIRU “Centro de Información de las Naciones Unidas”
http://www.cinu.mx/minisitio/ODM2011/docs/InformeODM2011.pdf, retrieved on
October 03 of 2011.
- Sources: elmundo.es
http://www.elmundo.es/elmundosalud/documentos/2010/11/onusida/est_mundo
_2010.html, retrieved on October 05 of 2011.
- Sources: MSD
http://www.msd.com.co/msdco/corporate/index.html, retrieved on October 05 of
2011.
- Sources: The Merck group
http://www.merckgroup.com/en/index.html, retrieved on October 06 of 2011.
- Sources: Merck
http://www.merck-chemicals.com/, retrieved on October 06 of 2011.
- Sources: The Merck manual
http://www.merckmanuals.com/professional/index.html, retrieved on October 06
of 2011.
- Sources: The sacramento bee
http://www.sacbee.com/2011/10/05/3961844/hivaids-therapeutics-market-
to.html, retrieved on October 06 of 2011.